Amneal Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive (Loss) Income
| Years Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net (loss) income | $(48,722) | $(254,789) | $20,170 |
| Less: Net (income) loss attributable to non-controlling interests | (35,271) | 125,241 | (9,546) |
| Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interest | (83,993) | (129,548) | 10,624 |
| Accretion of redeemable non-controlling interest | — | (438) | — |
| Net (loss) income attributable to Amneal Pharmaceuticals, Inc. | (83,993) | (129,986) | 10,624 |
| Other comprehensive (loss) income: | |||
| Foreign currency translation adjustments arising during the period | (1,059) | (26,891) | (8,618) |
| Unrealized (loss) gain on cash flow hedge, net of tax | (48,497) | 97,059 | 42,430 |
| Reclassification of cash flow hedge to earnings, net of tax | (3,366) | — | — |
| Less: Other comprehensive loss (income) attributable to non-controlling interests | 9,875 | (35,292) | (17,095) |
| Other comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc. | (43,047) | 34,876 | 16,717 |
| Comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc. | $(127,040) | $(95,110) | $27,341 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.